Gastrointestinal Pharmaceuticals: Technologies and Markets

Published by: BCC Research

Published: Sep. 1, 2009 - 196 Pages

Table of Contents

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY AND INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS)

SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS)

CHAPTER THREE: INDUSTRY OVERVIEW

STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM

INGESTION AND PROPULSION OF FOOD

Mouth

Pharynx

Esophagus

DIGESTION AND ABSORPTION

Mouth

Stomach

Small Intestines

Physiology of Digestion

ELIMINATION

Large Intestine

LIVER, BILIARY TRACT AND PANCREAS

LIVER

BILIARY TRACT

Bilirubin Metabolism

PANCREAS

GASTROINTESTINAL TRACT DISORDERS

DYSPHAGIA

ESOPHAGEAL AND ABDOMINAL PAIN

VOMITING

INTESTINAL GAS

CONSTIPATION

DIARRHEA

TABLE 1 CAUSES OF DIARRHEA

GASTROINTESTINAL TRACT WALL DISORDERS

GASTRITIS

TABLE 2 COMMON CAUSES OF GASTRITIS

GASTROENTERITIS

PEPTIC ULCER DISEASE

GASTRIC ULCERS

DUODENAL ULCERS

INFLAMMATORY BOWEL DISEASE

ULCERATIVE COLITIS

CROHN’S DISEASE

ENTEROCOLITIS

DIVERTICULAR DISEASE

GASTROINTESTINAL TRACT MOTILITY DISORDERS

IRRITABLE BOWEL SYNDROME

INTESTINAL OBSTRUCTION

GASTROINTESTINAL MALABSORPTION DISORDERS

CELIAC DISEASE

TROPICAL SPRUE

CANCERS OF THE GASTROINTESTINAL TRACT

ESOPHAGEAL CANCER

GASTRIC CANCER

LIVER CANCER

PANCREATIC CANCER

SMALL INTESTINAL CANCER

COLONIC POLYPS AND COLON CANCER

U.S. DEMOGRAPHICS

TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS

TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)

FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%)

PILL-SIZED VIDEO CAMERA

PILLCAM ESO

SMARTPILL

RADIO FREQUENCY IDENTIFICATION TECHNOLOGY

IPHONE APPLICATION

ENTERIC NERVOUS SYSTEM

INSURANCE COVERAGE

MONOCLONAL ANTIBODIES

WYETH IN SUIT WITH STATES

GENERIC INFLUENCE

BRANDED VS OTC PROTON PUMP INHIBITORS

MAIL ORDER TRENDS

CHAPTER FOUR: PRESCRIPTION PRODUCT SEGMENTS BY TYPE

ANTIDIARRHEALS

SYSTEMICALLY ACTING ANTIDIARRHEALS

OPIUM PRODUCTS

TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS

MARKET SIZE AND GROWTH

TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS)

ANTIEMETICS

LOCALLY ACTING ANTIEMETICS

CENTRALLY ACTING ANTIEMETICS

ANTIDOPAMINERGICS

ANTICHOLINERGICS

MISCELLANEOUS ANTIEMETICS

TABLE 8 MARKETED ANTIEMETIC PRODUCTS

MARKET SIZE AND GROWTH

TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

GASTROINTESTINAL CANCER TREATMENTS

TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS

MARKET SIZE AND GROWTH

TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS)

H2 INHIBITORS

TABLE 14 MARKETED H2 INHIBITORS PRODUCTS

MARKET SIZE AND GROWTH

TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS)

LAXATIVES

TABLE 17 MARKETED LAXATIVE PRODUCTS

MARKET SIZE AND GROWTH

TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS)

PROTON PUMP INHIBITORS

TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS

MARKET SIZE AND GROWTH

TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

BOWEL ANTI-INFLAMMATORY

TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS

MARKET SIZE AND GROWTH

TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

OTHER GASTROINTESTINAL PRODUCTS

ANTISPASMODICS

TABLE 26 MARKETED ANTISPASMODIC PRODUCTS

DIGESTANTS

GASTRIC ACIDIFIERS

PANCREATIC ENZYMES

TABLE 27 MARKETED DIGESTANT PRODUCTS

EVACUANTS

TABLE 28 MARKETED EVACUANTS PRODUCTS

MUCOSAL PROTECTANTS

TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS

PROSTAGLANDINS

TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS

STIMULANTS

TABLE 31 MARKETED STIMULANT PRODUCTS

MARKET SIZE AND GROWTH

TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE

TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH

TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS)

FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS)

TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS

TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009)

FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, 2009 ESTIMATED (%)

CHAPTER FIVE: OTC PRODUCT SEGMENTS BY TYPE

ANTACIDS

SYSTEMIC ANTACIDS

Sodium Bicarbonate

NONSYSTEMIC ANTACIDS

Calcium Carbonate

Aluminum Products

Magnesium Products

Combination Products

TABLE 35 MARKETED OTC ANTACID PRODUCTS

MARKET SIZE AND GROWTH

TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%)

LOCALLY ACTING ANTIDIARRHEALS

ADSORBENTS

INTESTINAL FLORA MODIFIERS

TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS

MARKET SIZE AND GROWTH

TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%)

H2 INHIBITORS

TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS

MARKET SIZE AND GROWTH

TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)

PROTON PUMP INHIBITORS

OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE)

TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS

MARKET SIZE AND GROWTH

TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)

LAXATIVES

TABLE 47 MARKETED OTC LAXATIVE PRODUCTS

MARKET SIZE AND GROWTH

TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%)

TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH

TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS)

FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS)

TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS

TABLE 51 TOTAL MANUFACTURERS’ REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%)

FIGURE 31 TOTAL MANUFACTURERS’ MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%)

RESEARCH AND DEVELOPMENT

METOSOLV ODT

NEXIUM LOW-DOSE ASPIRIN COMBINATION

REZONIC

SANVAR

TAK-390MR (KAPIDEX)

ZENPEP

AB-1001

ALICAFORSEN

APF 530

CROFELEMER

HUMIRA

LINACLOTIDE

METHYLNALTREXONE (MNTX) (RELSTAR)

MLN 0002 (VEDOLIZUMAB)

ORBEC

PROCHYMAL

RENZAPRIDE

REMICADE

REZULAR

RIFAXIMAN (XIFAXAN)

SUTENT

ALICAFORSEN ENEMA

DEXTOFISOPAM

EKB-569

GTI-2040

PUMOSETRAG

RDP-58

SORAPRAZAN

TALNETANT

BL-1030

BL-1050

TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT

TOTAL MARKET ANALYSIS

TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS)

FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS)

CHAPTER SIX: INDUSTRY PARTICIPANTS BY PRODUCT TYPE

TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%)

FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ MARKET SHARE BY TYPE, 2009 (%)

COMPANY PROFILES

ASTRAZENECA

History

AXCAN PHARMA, INC.

History

CENTOCOR, INC.

History

EISAI, INC.

History

GENENTECH, INC.

History

GLAXOSMITHKLINE

History

JOHNSON & JOHNSON

History

MCNEIL CONSUMER HEALTHCARE

History

MERCK & CO., INC.

History

NOVARTIS INTERNATIONAL AG

History

PFIZER, INC.

History

PROCTER & GAMBLE CO.

History

ROCHE

History

SANOFI-AVENTIS

History

SALIX PHARMACEUTICALS, LTD.

History

SOLVAY PHARMACEUTICALS

History

TAKEDA PHARMACEUTICALS NORTH AMERICA

History

WYETH

History

APPENDIX: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS

3M CORP.

ABBOTT LABORATORIES

ABEILLE PHARMA, INC.

ACAMBIS, PLC

ACE BIOSCIENCES A/S

AGI THERAPEUTICS, INC.

ALCHEMIA, LTD.

ALIZYME, PLC

ALLERGAN, INC.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

ALTANA PHARMA AG

ALVINE PHARMACEUTICALS, INC.

AMARIN CORP.

AMGEN, INC.

ANTIGENICS, INC.

APOTHECON B.V.

AP PHARMA, INC.

ARCO PHARMACEUTICALS

ASPHELIA PHARMACEUTICALS, INC.

ARYX THERAPEUTICS, INC

ASTELLAS PHARMA, INC.

ASTRAZENECA, PLC

AXCAN PHARMA, INC.

BERTEK (MYLAN LABORATORIES INC.)

BIOBALANCE, INC.

BIOGEN IDEC, INC.

BIOLINERX, LTD.

BRAINTREE LABORATORIES, INC.

BRISTOL-MYERS SQUIBB CO.

CELLDEX THERAPEUTICS, INC.

CENTOCOR ORTHO BIOTECH, INC.

CEPHALON, INC.

CERIMON PHARMA, INC.

CHEMOCENTRYX, INC.

CLAVIS PHARMA ASA

COSMO PHARMACEUTICALS SPA

CYTOKINE PHARMASCIENCES, INC.

DEBIOPHARM S.A

DOR BIOPHARMA, INC.

EISAI CO., LTD.

ELAN CORPORATION, PLC

EMD SERONO, INC.

ENZO

EURAND PHARMACEUTICALS, INC.

EVOKE PHARMA

FRESENIUS KABI AG

GENENTECH, INC.

GENZYME GENERAL

GLAXOSMITHKLINE, PLC

GLAXOSMITHKLINE CONSUMER HEALTHCARE

GLENMARK PHARMACEUTICALS, LTD.

H3 PHARMA, INC.

HELSINN HEALTHCARE

HOFFMAN-LAROCHE, LTD. (ROCHE)

HYPERION THERAPEUTICS, INC.

IMMUCELL CORP.

ISIS PHARMACEUTICALS. INC.

JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON)

JOHNSON & JOHNSON

LORUS THERAPEUTICS, INC.

MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS

MEDISCA, INC.

MERCK & CO., INC.

MONARCH LABS

NABI BIOPHARMACEUTICALS

NOVARTIS CORP.

NPS PHARMACEUTICALS, INC.

OTSUKA AMERICA PHARMACEUTICAL, INC.

PFIZER, INC.

THE PROCTER & GAMBLE CO.

PRODIGENE, INC.

PROGENICS PHARMACEUTICALS, INC.

RAVEN BIOTECHNOLOGIES, INC.

RELIANT PHARMACEUTICALS, INC.

ROXANE LABORATORIES, INC.

SALIX PHARMACEUTICALS, LTD

SANOFI-AVENTIS

SANTARUS, INC.

SCHERING AG

SCHWARZ PHARMA AG

SERONO S.A.

SHIRE PHARMACEUTICALS GROUP, PLC

SOLVAY S.A.

SUCAMPO PHARMACEUTICALS, INC.

SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC)

TAKEDA PHARMACEUTICAL NORTH AMERICA

TARGACEPT, INC.

THERAVANCE, INC.

UCB PHARMA, INC.

UNIMED PHARMACEUTICALS, INC.

PHARMOS PHARMACEUTICALS, INC.

WATSON PHARMACEUTICALS, INC.

WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.)

LIST OF TABLES

SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS)

TABLE 1 CAUSES OF DIARRHEA

TABLE 2 COMMON CAUSES OF GASTRITIS

TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS

TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)

TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS

TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 8 MARKETED ANTIEMETIC PRODUCTS

TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS

TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

TABLE 14 MARKETED H2 INHIBITORS PRODUCTS

TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

TABLE 17 MARKETED LAXATIVE PRODUCTS

TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS

TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS

TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)

TABLE 26 MARKETED ANTISPASMODIC PRODUCTS

TABLE 27 MARKETED DIGESTANT PRODUCTS

TABLE 28 MARKETED EVACUANTS PRODUCTS

TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS

TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS

TABLE 31 MARKETED STIMULANT PRODUCTS

TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS)

TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009)

TABLE 35 MARKETED OTC ANTACID PRODUCTS

TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS

TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS

TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS

TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 47 MARKETED OTC LAXATIVE PRODUCTS

TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)

TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS)

TABLE 51 TOTAL MANUFACTURERS’ REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%)

TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT

TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS)

TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%)

LIST OF FIGURES

SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS)

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)

FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%)

FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS)

FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS)

FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS)

FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS)

FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)

FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS)

FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009/%)

FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%)

FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%)

FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)

FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)

FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)

FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%)

FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS)

FIGURE 31 TOTAL MANUFACTURERS’ MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%)

FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS)

FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ MARKET SHARE BY TYPE, 2009 (%)

Abstract

• Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
• The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.